Annular atrophic lichen planus induced by anti‐HER2 antibodies

Pertuzumab and trastuzumab are monoclonal antibody inhibitors targeting human epidermal growth factor receptor 2 (HER‐2) and are increasingly being utilised in the management of HER2‐positive breast cancer, having been demonstrated to improve progression‐free survival in conjunction with docetaxel....

Full description

Saved in:
Bibliographic Details
Published in:Australasian journal of dermatology 2021-05, Vol.62 (2), p.210-212
Main Authors: Chawla, Sumir, Turner, Nicholas, Terlizzo, Monica, Heelan, Kara
Format: Article
Language:English
Subjects:
annular atrophic lichen planus
Breast cancer
Epidermal growth factor
ErbB-2 protein
Lichen planus
lichenoid drug eruption
Metastases
Monoclonal antibodies
pertuzumab
Skin eruptions
Trastuzumab
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Pertuzumab and trastuzumab are monoclonal antibody inhibitors targeting human epidermal growth factor receptor 2 (HER‐2) and are increasingly being utilised in the management of HER2‐positive breast cancer, having been demonstrated to improve progression‐free survival in conjunction with docetaxel. We present a rare presentation of a lichenoid drug eruption, in an annular atrophic variant, in a 35‐year‐old woman after initiation of HER2‐inhibitor (pertuzumab and trastuzumab) therapy for metastatic breast cancer.
ISSN:0004-8380
1440-0960
DOI:10.1111/ajd.13501